cancer biology, developmental biology, epigenetics, genomics, precision medicine, gene regulation
Journal Articles
(2023)
Unraveling Connective Tissue Growth Factor as a Therapeutic Target and Assessing Kahweol as a Potential Drug Candidate in Triple Negative Breast Cancer Treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
22
(2023)
Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
21
(2023)
AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma.
FRONTIERS IN MOLECULAR BIOSCIENCES.
10,
(2022)
Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
CANCER MEDICINE.
12,
6
(2022)
Systematic Analysis of Cellular Signaling Pathways and Therapeutic Targets for SLC45A3:ERG Fusion-Positive Prostate Cancer.
JOURNAL OF PERSONALIZED MEDICINE.
12,
11
(2022)
Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion.
BIOMEDICINES.
10,
10
(2022)
Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in NSCLC.
ISCIENCE.
25,
11
(2022)
Unique characteristics of lung resident neutrophils are maintained by PGE2/PKA/Tgm2-mediated signaling.
BLOOD.
140,
8
(2021)
Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer.
CLINICAL AND TRANSLATIONAL MEDICINE.
11,
5
(2021)
Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice.
NATURE MICROBIOLOGY.
6,
3
(2020)
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma.
ISCIENCE.
23,
8
(2020)
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
CANCER.
126,
11
(2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients.
ANNALS OF ONCOLOGY.
31,
7
(2020)
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity.
NATURE COMMUNICATIONS.
11,
1
(2019)
Chromatin establishes an immature version of neuronal protocadherin selection during the naïve to primed conversion of pluripotent stem cells.
NATURE GENETICS.
51,
12
(2019)
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
NATURE COMMUNICATIONS.
10,
1
(2019)
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
EUROPEAN JOURNAL OF CANCER.
120,
(2019)
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitor.
JOURNAL OF THORACIC ONCOLOGY.
14,
9
(2019)
MED28 Over-Expression Shortens the Cell Cycle and Induces Genomic Instability.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
20,
7
(2018)
Pluripotency factors functionally premark cell-type-restricted enhancers in ES cells..
NATURE.
556,
7702
